SERI’s ocular surface research group engages in a highly competitive, international level research related to the ocular surface. The main focus is on the diagnosis and treatment of ocular surface diseases, such as dry eye, meibomian gland dysfunction and pterygium. They are also focused on understanding the molecular basis of these diseases. This type of research ranges from epidemiology, health services, biochemicals, cell- and animal-based research to imaging and human clinical trials.
In recent years, the group has performed research related to conjunctival T cells, induction of immune-mediated ocular surface inflammation in animals, the effects of S100 calcium-binding proteins and the regulation of wound healing by molecules such as transglutaminase-2. The group is dedicated to the evaluation and use of state-of-the-art technologies in dry eye, such as tear protein biomarkers, non-invasive meibography, tear evaporimetry, and tear eicosanoid lipid analysis by mass spectrometry. It is currently very active in various projects with commercial potential, such as the preclinical evaluation of anti-inflammatory drugs and tear stabilizing formulations.
As part of the effort to translate research findings into clinical care, the ocular surface research group has published in topics, such as autologous plasma drops for recalcitrant dry eye, thermopulsation treatment, eyelid warming, moisture chamber glasses, patient focus groups and education on use of eyelid wipes. The Principal Investigator actively contributes to the international Dry Eye Workshop 2, the Meibomian Gland Dysfunction International Workshop, the Asia Dry Eye Society Council and the Asia Cornea Society. He is a global ambassador for the Tear Film and Ocular Surface Society. The emphasis, therefore, is not only in innovative research, but also in the promotion and education of the public and health professionals to champion the healthcare needs of patients with ocular surface diseases.
The ocular surface research lab houses cutting edge facilities and equipment, such as centricollation system (Prospect Biosystems), flow cytometry facility (BD), cell impedence tracking device (xCELLigence, Roche), microscopy imaging station and basic laboratory setups, including qPCR machines (Roche), film development and cell culture facilities.
Tong L, Seow G, Tan J, Thumboo J. Dry eye practice pointer. BMJ. 2012; 345:e7533.
Tong L et al. The eye: A window of opportunity in rheumatoid arthritis? Nature Reviews Rheumato.2014 Jun 10.doi: 0.1038/nrrheum.2014.85.
Waduthantri S, Yong SS, Htoon HM, Tong L. Randomised controlled trial of Systane Ultra® vs Refresh Tears® in Asian dry eye patients. Optom Vis Sci. 2012; 89: 1647-53.
Lam SM, et al. Extensive characterization of human tear fluid collected using different techniques unravels the presence of novel lipid amphiphiles. J Lipid Res. 2014 Feb;55(2):289-98. doi: 10.1194/jlr.M044826.
Koh YW, Celik T, Lee HK, Petznick A, Tong L. Detection of meibomian glands and classification of meibography images. J Biomed Opt. 2012; 17(8):086008.
Tong L, Png E, Hou AH, Yong SS, Yeo HL, Riau A, Mendoze E, Charausiaa SS, Lim CT, Yiu TW, Iismaa SE. Molecular Mechanism of Transglutaminase-2 in Corneal Epithelial Migration and Adhesion. BiochimBiophysActa 2013;1833:1304-1315.
Png E, Samivelu GK, Yeo SH, Chew J, Chaurasia SS, Tong L. Hyperosmolarity mediated mitochondrial dysfunction requires transglutaminase-2 in human corneal epithelial cells. J Cell Physiol. 2011; 226: 693–699.
DA Schaumberg, JJ Nichols, EB Papas, L Tong, M Uchino, KK Nichols. The international workshop on meibomian gland dysfunction: Report of the subcommittee on the epidemiology of, and associated risk factors for, MGD. Invest Ophthalmol Vis Sci. 2011; 52 (4): 1994-2005.
Lan, Wanwen; Chen, Silin; Tong, Louis. MicroRNA-215 Regulates Fibroblast Function: Insights from a Human Fibrotic Disease. Cell Cycle. 2015 Jun 18;14(12):1973-84. doi: 10.1080/15384101.2014.998077.
Riau AK, Wong TT, Finger SN, Lan WW, Chaurasia SS, Hou AH, Chen SL, Yu SJ, Tong L. Aberrant DNA methylation of matrix remodeling and cell adhesion related genes in pterygium. PLOS One. 2011; 6(2): e14687.
Selva KJ, Liu YC, Siak JK, Lan WW, Tong L, Yawata M, Mehta JS, Yawata N, Dynamic change in natural killer cell type in the human ocular mucosa in situ as means of immune evasion by adenovirus infection. Mucosal Immunol 2015 Jun 17. doi: 10.1038/mi.2015.47.
Gong L, Sun XH, Ma ZZ, et al, Tong L. A Randomized, Parallel-Group Comparison Study of Diquafosol Ophthalmic Solution in Patients with Dry Eye (Comparison with 0.1% sodium hyaluronate ophthalmic solution) in China and Singapore. Br J Ophthalmol. 10.1136/bjophthalmol-2014-306084.
ManpowerThe ocular surface research team is led by a clinician scientist, Associate Professor Louis Tong, and currently comprises of a post-doctoral research fellow, two graduate students, two research optometrists, one project coordinator and one research assistant. The group is dedicated to nurturing post- and undergraduate medical students, undergraduate final year project students as well as polytechnic students who are welcome to join the lab for long or short term attachments.
Grant SupportOur research is supported by national competitive grants (e.g. National Medical Research Council) including 2 clinician-scientist awards, one individual research grant, the Biomedical Research Council Translational Clinical Research Project grant, 2 international awards, as well as various sources of industrial funding.
Prof Louis Tong
Senior Research Fellow
Dr Hou Ai Hua
Senior Research Technologist
Tin Min Qi
Subscribe to our mailing list to get the updates to your email inbox...